---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-031715"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:48:05.736184+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Armata delays Q4/FY2025 earnings; FDA grants QIDP for phage candidate AP-SA02

## Summary
- Will delay Q4/FY2025 financial results announcement; expects to file 10-K by March 31, 2026 due date.
- FDA granted QIDP for AP-SA02 (S. aureus phage) as adjunct treatment for complicated bacteremia, adding Hatch-Waxman exclusivity.
- FDA alignment reached on Phase 3 superiority study design; Armata plans to initiate study in H2 2026.
- cGMP manufacturing facility in Los Angeles (~56,000 sq ft) formally commissioned; full production runs completed.
- Phase 2a diSArm study showed higher cure rates with AP-SA02 plus antibiotics vs antibiotics alone; results presented at IDWeek 2025.

## SEC filing metadata
- accession: 0001104659-26-031715
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/0001104659-26-031715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926031715/tm269341d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-031715
- JSON: https://secwatch.observer/filing/0001104659-26-031715.json
- Plain text: https://secwatch.observer/filing/0001104659-26-031715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.